Gossamer Bio, Inc. (NASDAQ: GOSS) said on July 27, 2026, that it plans to submit a New Drug Application for investigational inhaled seralutinib in pulmonary arterial hypertension in September, following a Pre-NDA Type B meeting with the United States Food and Drug Administration and receipt of the agency’s final meeting minutes. The clinical-stage biotechnology company also reacquired worldwide development and commercial rights to seralutinib from Chiesi Group, completed a debt exchange intended to reduce principal obligations and reported preliminary cash, cash equivalents and marketable securities of approximately $57 million at June 30.
The package of announcements gives Gossamer Bio a clearer route to placing seralutinib before FDA reviewers, but it does not resolve the central question created by the Phase 3 PROSERA trial. The study’s primary endpoint produced a numerical benefit that met the conventional p-value threshold of 0.05 but missed the stricter prespecified statistical threshold written into the trial design.
That distinction now defines the regulatory case. Gossamer Bio has moved from uncertainty over whether an application could be submitted to a position in which the FDA appears willing to review the full evidence package. Whether that evidence can support approval remains open, and the company must pursue that process with less cash, no active development partner and a share price that reflects substantial investor scepticism.
How much regulatory ground did Gossamer Bio gain from the FDA Pre-NDA meeting?
Gossamer Bio said the FDA characterised the degree of statistical significance and magnitude of the PROSERA treatment effect as review issues rather than filing issues. In practical terms, the agency’s feedback appears to mean that the statistical outcome does not, by itself, prevent Gossamer Bio from assembling and submitting an application.
That is a meaningful procedural advance. Before the meeting, the company could not be certain that the FDA would regard the proposed evidence package as suitable for an NDA submission following a pivotal study that missed its prespecified alpha threshold. The meeting minutes have allowed management to proceed with a September filing target and to organise the application around PROSERA as one adequate and well-controlled investigation, supported by Phase 2 TORREY data and additional analyses.
The wording should not be interpreted as an informal endorsement of approval. A filing decision principally considers whether an application is sufficiently complete to permit substantive review. The eventual assessment will examine whether the evidence establishes effectiveness, whether the magnitude of benefit is clinically persuasive, whether the statistical analysis is reliable and whether the benefit-risk balance supports the proposed indication.
Gossamer Bio has acknowledged that the FDA will make its approvability determination only after reviewing the complete application. Should the NDA be submitted in September and accepted for filing, the company believes seralutinib could become eligible for an approval decision during the third quarter of 2027. Both the filing acceptance and decision timeline therefore remain conditional.
Why does the PROSERA statistical miss remain central to seralutinib’s approval prospects?
PROSERA was a Phase 3, randomised, double-blind and placebo-controlled trial involving 390 adults with World Health Organization Functional Class II or III pulmonary arterial hypertension. Participants were already receiving background pulmonary arterial hypertension therapy and were assigned to inhaled seralutinib or placebo, with change in six-minute walk distance at Week 24 serving as the primary endpoint.
Seralutinib produced a placebo-adjusted improvement of 13.3 metres in six-minute walk distance, with a p-value of 0.0320. The trial had assigned an alpha threshold of 0.025 to the primary analysis, meaning the result did not satisfy the statistical criterion established before the study began.
The difference between 0.0320 and 0.025 may appear small, but prespecified thresholds exist to control the probability of false-positive conclusions. A result cannot be reclassified as a successful primary endpoint merely because it falls below the more familiar 0.05 threshold.
The statistical miss also affects the formal interpretation of secondary endpoints. Although the company reported that all four key secondary outcomes favoured seralutinib, their p-values must be regarded as nominal because the primary endpoint did not meet its allocated alpha. The findings may strengthen the totality of evidence, but they cannot simply be treated as independently confirmed statistical successes under the trial’s hierarchical testing structure.
The most prominent supportive signals came from patients categorised as intermediate or high risk at screening. In this prespecified subgroup of 234 participants, seralutinib produced a placebo-adjusted 20-metre improvement in six-minute walk distance. The company also reported favourable changes in NT-proBNP, clinical improvement and REVEAL Lite 2 risk score.
Patients with connective tissue disease-associated pulmonary arterial hypertension showed a reported placebo-adjusted improvement of 37 metres, although that analysis involved 87 patients and remains a subgroup finding rather than the trial’s primary result. Such findings may help regulators identify whether activity was concentrated in particular patients, but subgroup consistency, multiplicity and the intended breadth of the proposed label will require detailed examination.
Safety will form another part of that assessment. Treatment-emergent adverse events occurred in 86.5% of seralutinib recipients and 80.5% of placebo recipients, while serious treatment-emergent adverse events occurred in 16% and 18.9%, respectively. Cough was the most frequently reported adverse event with seralutinib, affecting 37% of treated patients.
Transaminase elevations reaching at least three times the upper limit of normal occurred in 13% of seralutinib recipients, compared with 1% of placebo recipients. That imbalance does not establish that the drug has an unacceptable safety profile, but it is a material signal that regulators will evaluate alongside exposure, reversibility, clinical consequences and proposed monitoring requirements.
Can TORREY and supportive analyses provide enough confirmatory evidence for the FDA?
The regulatory strategy relies on a recognised pathway under which one adequate and well-controlled investigation may be supported by confirmatory evidence. FDA guidance makes clear that such evidence can come from different sources, depending on the disease, development programme, biological rationale and strength of the pivotal result.
TORREY provides the most conventional component of Gossamer Bio’s confirmatory package. The Phase 2 randomised, double-blind and placebo-controlled trial enrolled 86 adults with pulmonary arterial hypertension receiving background therapy. Seralutinib met the study’s primary endpoint by reducing pulmonary vascular resistance relative to placebo after 24 weeks.
The peer-reviewed study reported a placebo-adjusted difference of minus 96.1 dyne-seconds per square centimetre to the fifth power in pulmonary vascular resistance, with a p-value of 0.03. The study therefore supplied controlled human evidence of pharmacological activity on a haemodynamic measure relevant to pulmonary arterial hypertension.
Its limitations are equally important. TORREY was considerably smaller than PROSERA, and its primary endpoint was pulmonary vascular resistance rather than the six-minute walk distance endpoint used in the pivotal study. It can corroborate biological and haemodynamic activity, but it does not duplicate the Phase 3 efficacy test.
Longer-term observations from the TORREY open-label extension may provide additional information on durability and tolerability. Those analyses were descriptive and lacked a concurrent placebo control. Treatment-emergent adverse events led to seralutinib discontinuation in 27% of extension participants, with cough cited as the reason in 12.2%.
Gossamer Bio also intends to use supportive analyses from PROSERA, including exploratory computed tomography functional respiratory imaging findings. The company has reported treatment-associated imaging changes across arterial, venous and fibrosis-related measures, with correlations to clinical outcomes.
Those findings may strengthen the mechanistic argument, particularly for a therapy designed to target proliferative, inflammatory and fibrotic pathways rather than functioning solely as a vasodilator. However, the reported imaging p-values were nominal and were not adjusted for multiplicity. Exploratory imaging evidence can support interpretation, but it is unlikely to substitute independently for a convincing clinical treatment effect.
What does regaining worldwide seralutinib rights from Chiesi change for Gossamer Bio?
Gossamer Bio and Chiesi Group have agreed to terminate the collaboration and licence agreement established in May 2024. Under that earlier structure, the companies shared United States profits and losses equally, divided certain global development costs and gave Chiesi exclusive commercial rights outside the United States, with Gossamer Bio eligible for royalties.
The termination returns worldwide development, manufacturing, pricing, commercialisation and lifecycle control to Gossamer Bio. The company said it will make no upfront payment to reacquire the rights. Chiesi will instead make a one-time $5 million payment to settle outstanding and future obligations under the collaboration, including second-quarter 2026 costs.
Chiesi will retain rights to a capped royalty on worldwide net sales and specified regulatory and commercial milestone payments. Once the sales royalty reaches its agreed cap, no additional royalty obligation will apply.
For Gossamer Bio, the transaction creates considerably greater economic exposure to any future success. The company no longer has to divide United States profits equally or rely primarily on an ex-United States royalty stream. It can also control the geographic sequence, pricing strategy and development priorities for seralutinib.
Greater economics arrive with greater responsibility. Gossamer Bio is taking back a late-stage programme as it approaches an NDA submission, potential regulatory review, manufacturing preparation and possible commercial build-out. It is losing the development cost sharing and international commercial capabilities that the Chiesi collaboration was originally intended to provide.
The companies did not disclose a detailed explanation for ending the partnership. It would therefore be inappropriate to portray the termination either as evidence that Chiesi rejected seralutinib’s prospects or as independent validation of Gossamer Bio’s confidence. The disclosed facts show that Gossamer Bio has chosen to assume control and that Chiesi will retain limited contingent economics.
Does the debt exchange solve Gossamer Bio’s financing challenge before FDA review?
Gossamer Bio has exchanged approximately $181.1 million of its $200 million in 5% convertible senior notes due in 2027 for approximately $65.2 million of new 7.5% convertible senior secured first-lien notes due in 2030, together with equity securities and warrants. The transaction reduced aggregate debt principal by approximately $115.9 million and left about $18.9 million of the original notes outstanding.
The restructuring materially lowers the principal amount and extends much of the maturity profile. It does not eliminate financing pressure. The replacement debt carries a higher interest rate, is secured and introduces equity-linked instruments that may contribute to dilution.
Preliminary cash, cash equivalents and marketable securities stood at approximately $57 million on June 30, down from $99.2 million at March 31. Before the latest changes, management had indicated that its first-quarter cash position could fund operations into the first quarter of 2027. The lower June balance, the end of Chiesi’s cost sharing and the requirements of an NDA review and potential launch make future capital needs a central part of the seralutinib investment case.
The authorised reverse stock split addresses a separate problem. Gossamer Bio said the measure would provide flexibility to support compliance with Nasdaq’s minimum bid-price requirement. A reverse split can raise the nominal share price by reducing the number of shares outstanding, but it does not increase the company’s underlying enterprise value or remove clinical and financing risks.
Gossamer Bio shares closed at $0.136 on July 24, approximately 20% below their July 17 close and near the bottom of a 52-week range of $0.114 to $3.87. The implied market capitalisation was approximately $32 million. Premarket trading on July 27 pointed to a gain of more than 20% following the announcement, although that early response had not been tested during regular market trading and remained vulnerable to the volatility typical of a low-priced biotechnology stock.
The market position indicates that investors continue to assign a high probability to dilution, regulatory difficulty or both. The FDA meeting provides a catalyst, but a filing path is not the same as regulatory de-risking.
What happens to the PH-ILD programme now that Gossamer Bio owns the global rights?
Seralutinib is also being investigated for pulmonary hypertension associated with interstitial lung disease through the Phase 3 SERANATA programme. Enrollment was paused after the PROSERA result while the company considered regional placebo-response differences and the wider implications for development strategy.
The ClinicalTrials.gov record subsequently listed SERANATA as suspended following a sponsor decision. The July 27 update returned global ownership of the programme to Gossamer Bio but did not announce a restart, redesigned protocol or new development timetable.
That leaves the PH-ILD opportunity strategically valuable but operationally uncertain. Restarting a global Phase 3 programme would require substantial capital, particularly now that Gossamer Bio no longer has Chiesi sharing development costs. Management may need to prioritise the pulmonary arterial hypertension NDA, seek another partnership, redesign the study or defer further PH-ILD investment until the regulatory position in pulmonary arterial hypertension becomes clearer.
This decision matters because Gossamer Bio has become heavily dependent on one investigational asset. Worldwide rights increase the value retained from any approved indication, but they also concentrate clinical, regulatory and financial exposure around seralutinib.
What will determine whether the September NDA becomes a credible 2027 approval opportunity?
The next measurable milestone is submission of a complete NDA in September. Acceptance for filing would confirm that the FDA considers the application sufficiently complete for review, but the harder test will begin after that procedural decision.
Reviewers will need to decide whether PROSERA can be considered an adequate and well-controlled investigation supporting effectiveness despite missing its prespecified alpha threshold. They will also assess whether TORREY, biomarker changes, imaging analyses, subgroup findings and longer-term data provide confirmatory evidence strong enough to compensate for the pivotal result’s statistical weakness.
The proposed indication will matter. A broad pulmonary arterial hypertension label would require confidence that the treatment effect applies across the intended population. A narrower population could potentially align more closely with the stronger intermediate-risk, high-risk or connective tissue disease-associated findings, but any such approach would have to be supported prospectively and not constructed solely from favourable subgroup results.
Regulators will separately examine liver enzyme elevations, cough, treatment discontinuation, inhaler use, manufacturing controls and the complete benefit-risk profile. Gossamer Bio must also demonstrate that it can finance the review period and build the manufacturing and commercial capabilities previously expected to be shared with Chiesi.
The July update has changed seralutinib’s position from a programme facing an uncertain regulatory route into one heading toward a formal application. It has not converted the PROSERA result into a successful Phase 3 endpoint, nor has it removed the need for capital.
The decisive question is no longer whether Gossamer Bio can submit seralutinib to the FDA. It is whether the full evidence package can persuade reviewers that a reproducible and clinically meaningful benefit exists despite the pivotal study’s prespecified statistical miss, and whether the company can remain adequately financed long enough to reach that decision.
